Where Do Your Funds Go?

Over the past 11 years, Miles for Moffitt has raised over $3.2 million to fund critical research at Moffitt Cancer Center. Each year, Moffitt researchers submit proposals for Miles for Moffitt grant funding. All proposals go through a two-stage review process. The first stage is internal peer-review overseen by the Grant Review Committee (GRC). The GRC members include our research Program Leaders and ad hoc members as needed to ensure an expert, impartial review, as well as even distribution of workload. Members of the committee are assigned primary and secondary reviews and then convene an NCI-style review session utilizing NCI scoring (1–9). Proposals are ranked based on the quality of the science and adherence to the guidelines. The best (lowest score) proposals are funded until the available award pool is reached. The second stage review process for Miles for Moffitt awards is completed by the Research Executive Committee (REX). REX takes into consideration the recommendations of the review committee and makes the final funding decisions. With the 2016 Miles for Moffitt funds, $600,000 was awarded in the form of six Miles for Moffitt grant awards at $100,000 each, at the 2016 Scientific Symposium, held the week of the race.

 

 

Miles for Moffitt Awardees 2016

Junior Faculty

Uwe Rix, PhD
Fibroblast-mediated drug resistance and sensitization of lung cancer cells
Assistant Member, Chemical Biology and Molecular Medicine

Stephanie Schmit, PhD
Microbes in the tumor microenvironment: bacterial influences on host immunity and prognosis in colorectal cancer
Assistant Member, Cancer Epidemiology

AND

Christine Pierce Campbell, PhD
Assistant Member, Cancer Epidemiology

Eric Lau, PhD
Roles of fucosylation in melanoma: immune cell biology
Assistant Member, Chemical Biology and Molecular Medicine

Bradford Perez, MD
Evaluating combined immune checkpoint blockade, ablative radiation therapy and intratumoral injection of dendritic cells in a preclinical mouse model lung cancer
Assistant Member, Immunology

Senior Faculty

Jianguo Tao, MD, PhD
Pharmacoproteomics identifies combinatorial therapy for aggressive large B cell lymphoma
Senior Member, Cancer Biology and Evolution

Gary Reuther, PhD
Targeting proteostatic regulation requisite for myeloid neoplasms
Associate Member, Cancer Biology and Evolution